SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2020.07.08 | 23:01 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS - HTML (w)

2020.07.08 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease - HTML (w)

2020.06.10 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment - HTML (w)

2020.06.04 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020 - HTML (w)

2020.05.28 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science - HTML (w)

2020.05.19 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS - HTML (w)

2020.05.18 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients - HTML (w)

2020.04.27 | 22:06 | Permanent Information Releases / Operations

English version HTML (w) Mail

puce Biogen Prices $3.0 Billion of Senior Unsecured Notes - HTML (w)

2020.04.22 | Periodic information / 1st Quarter Information

English version PDF Mail

puce Biogen Idec Inc : First quarter 2020 financial results - PDF (402Kb)

2020.04.20 | 23:45 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics - HTML (w)

2020.04.16 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank - HTML (w)

2020.04.02 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study - HTML (w)

2020.03.16 | 21:09 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World - HTML (w)

2020.02.27 | 22:06 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases - HTML (w)

2020.02.06 | Periodic information / Annual Financial Report

English version PDF Mail

puce Biogen Idec Inc : ANNUAL REPORT 2019 - PDF (4Mb)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 / Doc nb : 99